Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.740
-0.110 (-3.86%)
At close: Aug 1, 2025, 4:00 PM
2.740
0.00 (0.00%)
After-hours: Aug 1, 2025, 4:00 PM EDT

Company Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders.

The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass.

It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations.

Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

Alaunos Therapeutics, Inc.
Alaunos Therapeutics logo
CountryUnited States
Founded1998
IndustryBiotechnology
SectorHealthcare
Employees1
CEOHolger Weis

Contact Details

Address:
2617 Bissonnet Street, Suite 233
Houston, Texas 77005
United States
Phone346 355 4099
Websitealaunos.com

Stock Details

Ticker SymbolTCRT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001107421
CUSIP Number98973P101
ISIN NumberUS98973P3091
Employer ID84-1475642
SIC Code2834

Key Executives

NamePosition
Holger Weis CPAChairman of the Board and Chief Executive Officer
Ferdinand GroenewaldVice President of Finance

Latest SEC Filings

DateTypeTitle
Jul 22, 20258-KCurrent Report
Jul 17, 20258-KCurrent Report
Jul 10, 20258-KCurrent Report
Jul 2, 20258-KCurrent Report
Jul 1, 2025SCHEDULE 13DFiling
Jun 26, 20258-KCurrent Report
Jun 26, 20258-KCurrent Report
Jun 24, 2025424B3Prospectus
Jun 10, 20258-KCurrent Report
May 23, 20258-KCurrent Report